Trading Window Closure for the Quarter ended 30th September, 2026.
Scrutinizer Report and Voting Results
Press Release regarding EDQM approval for new product Rivaroxaban API, USFDA DMF Clearances.
We would like to inform you that the relevant information required to be disclosed under applicable laws has already been disclosed to the stock exhange from time to time in the recent past under Regulation 30 of the SEBI (LODR) Regulations, 2015. There is no other material event or information which needs to be informed to the stock exchanges at this point of time. The Company shall continue to disclose all relevant events or information in accordance with the timeliness prescribed under applicable laws and regulations. Therefore, the increase in the price of the scrip of the Company in the recent past is completely market driven.
Resolution passed through circulation by the Board of Directors of the Company regarding early redemption in full of 12.5% secured, guaranteed, senior, taxable, non-cumulative, unrated, redeemable, principal protected non-convertible debentures issued by the company.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd
Closure of Trading Window
Closure of Trading Window
Press Release dated 25.06.2026 titled Intimation of pledge being released on equity shares held by the Promoter Group and reduction in rate of interest from 12.5% per annum to Sub 10% per annum.
Press Release dated 25.06.2026 titled Intimation of pledge being released on equity shares held by the Promoter Group and reduction in rate of interest from 12.5% per annum to Sub 10% per annum.